- Home
- SIG vs IMVT Comparison
SIG vs IMVT Comparison
Compare SIG & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIG
- IMVT
- Stock Information
- Founded
- SIG 1950
- IMVT 2018
- Country
- SIG Bermuda
- IMVT United States
- Employees
- SIG N/A
- IMVT N/A
- Industry
- SIG Consumer Specialties
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SIG Consumer Discretionary
- IMVT Health Care
- Exchange
- SIG Nasdaq
- IMVT Nasdaq
- Market Cap
- SIG 3.1B
- IMVT 2.7B
- IPO Year
- SIG N/A
- IMVT N/A
- Fundamental
- Price
- SIG $81.92
- IMVT $15.22
- Analyst Decision
- SIG Buy
- IMVT Buy
- Analyst Count
- SIG 6
- IMVT 11
- Target Price
- SIG $90.33
- IMVT $35.88
- AVG Volume (30 Days)
- SIG 775.4K
- IMVT 1.3M
- Earning Date
- SIG 09-02-2025
- IMVT 08-11-2025
- Dividend Yield
- SIG 1.55%
- IMVT N/A
- EPS Growth
- SIG N/A
- IMVT N/A
- EPS
- SIG 0.86
- IMVT N/A
- Revenue
- SIG $6,734,600,000.00
- IMVT N/A
- Revenue This Year
- SIG $1.41
- IMVT N/A
- Revenue Next Year
- SIG $1.07
- IMVT N/A
- P/E Ratio
- SIG $95.75
- IMVT N/A
- Revenue Growth
- SIG N/A
- IMVT N/A
- 52 Week Low
- SIG $45.55
- IMVT $12.72
- 52 Week High
- SIG $106.28
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- SIG 56.12
- IMVT 41.11
- Support Level
- SIG $73.63
- IMVT $14.32
- Resistance Level
- SIG $83.91
- IMVT $16.18
- Average True Range (ATR)
- SIG 2.54
- IMVT 0.76
- MACD
- SIG 0.42
- IMVT -0.15
- Stochastic Oscillator
- SIG 74.95
- IMVT 32.14
About SIG Signet Jewelers Limited
Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Off-Mall & Outlet.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.